The World Health Organization has classified antimicrobial resistance (AMR) as one of the top global public health and development threats. In an October 2025 WHO update, the agency warned of widespread resistance to common antibiotics worldwide, reporting that one in six laboratory-confirmed bacterial infections showed resistance to common antibiotics and that resistance rates had increased by 5% to 15% in recent years. Combined with pandemic-era disruptions, persistent overuse in medicine and agriculture, and a thin pipeline of new drugs, AMR is increasingly described by public-health officials as a “silent pandemic” that could contribute to millions of deaths in the coming decades.
U.S. Infections and Deaths Keep Rising
The scale of antibiotic-resistant infections inside the United States has grown sharply over the past decade. According to the CDC’s 2019 Antibiotic Resistance Threats Report, more than 2.8 million antibiotic-resistant infections occurred annually in the U.S., causing more than 35,000 deaths. That represented a significant upward revision from earlier CDC estimates, which placed the annual toll at approximately 2 million illnesses and 23,000 deaths. The agency classifies resistant organisms into urgent, serious, concerning, and watch list categories, and several of the most dangerous pathogens have continued to spread despite targeted interventions.
The COVID-19 pandemic then reversed years of incremental progress. Detection and reporting of resistant infections slowed during 2020, even as healthcare-associated resistant infections and deaths increased. CDC reported that resistant healthcare-associated infections and related deaths increased during the first year of the pandemic. Six types of bacterial hospital-onset antimicrobial-resistant infections increased by a combined 20 percent during the pandemic period, peaking in 2021 and remaining above pre-pandemic levels in 2022, according to the agency’s 2021–2022 threat update. Clinical cases of the drug-resistant fungus Candida auris increased nearly five-fold from 2019 to 2022, signaling that the threat extends well beyond bacteria.
Global Death Toll and Forecasts Through 2050
The crisis is not confined to wealthy nations with large hospital systems. A peer-reviewed systematic analysis published in The Lancet estimated deaths and disability-adjusted life years attributable to and associated with bacterial antimicrobial resistance for 23 pathogens and 88 pathogen–drug combinations across 204 countries and territories in 2019. That study became the quantitative foundation for global mortality estimates cited in policy discussions worldwide. A subsequent Lancet analysis extended the timeline, estimating AMR deaths associated and attributable from 1990 to 2021 and forecasting outcomes to 2050 under multiple scenarios, with projected increases broken down by age group. According to the University of Pennsylvania’s Institute for Infectious and Inflammatory Health, antibiotic resistance threatens to kill 208 million people over the next 25 years if current trends continue unchecked.
Those projections carry particular weight for children and older adults, who face the highest vulnerability to infections that no longer respond to first-line drugs. The economic costs are also substantial. The WHO has noted that AMR carries significant economic costs, straining health budgets through longer hospital stays, more expensive second- and third-line treatments, and lost productivity. For middle-income countries with weaker surveillance systems, the true burden is likely even higher than current estimates capture, because many resistant infections go undiagnosed and unreported.
What Drives Resistance and Why It Keeps Spreading
The central driver is straightforward: antibiotic use itself. When antibiotics are administered, some bacteria survive and pass resistant traits to the next generation. That selective pressure intensifies with every unnecessary prescription, incomplete course of treatment, or subtherapeutic dose. Australia’s national AMR authority states plainly that the main cause of antibiotic resistance is antibiotic use, compounded by factors such as eating contaminated food and receiving medical treatment overseas. But the problem extends far beyond hospitals and clinics. Prophylactic and therapeutic antimicrobial misuse and overuse, along with the use of antimicrobials as feed additives in livestock production, contribute to the spread of resistance through food chains and the environment, according to research published in Frontiers in Microbiology.
Most public discussion focuses on human medicine, but agricultural use deserves equal scrutiny. Subinhibitory and subtherapeutic antibiotic concentrations in animal feed create ideal conditions for resistance genes to develop and transfer between bacterial species. Those resistant organisms then reach humans through the food supply, direct animal contact, and environmental contamination of water and soil. The result is a feedback loop that no single sector can break alone, which is why researchers and policymakers have increasingly pushed for a “One Health” approach that addresses resistance across human medicine, veterinary practice, and environmental management simultaneously.
Global Policy Response Falls Short
World leaders convened at the United Nations General Assembly in New York on September 26, 2024, with antimicrobial resistance as a focal point of discussions. That high-level session aimed to propose an enhanced framework to address the urgent threat, building on earlier pledges that had produced limited concrete results. A report drawing on data from over 100 countries described the situation as a “silent pandemic” in which common infections are becoming harder to treat with available drugs. Yet reporting on the meeting emphasized that translating pledges into sustained funding for new antibiotic development and global surveillance infrastructure remains a challenge.
The gap between political rhetoric and practical investment is the most dangerous aspect of the current moment. New antibiotic development stands in sharp contrast to demand, with few pharmaceutical companies willing to pursue drugs that are costly to discover but must be used sparingly to preserve effectiveness. A 2024 analysis in The Lancet highlighted how market failures, regulatory hurdles, and stewardship requirements have combined to produce a fragile pipeline in which only a small number of candidates target the most critical resistant pathogens. Without new economic incentives and global coordination, experts warn that the world will continue to rely on aging drugs while resistance steadily erodes their utility.
Surveillance, Stewardship, and the Path Forward
Strengthening surveillance is one of the clearest priorities. In the United States, the Centers for Disease Control and Prevention has expanded national laboratory networks and data systems to track resistant infections, building on earlier work such as a 2016 report in the Morbidity and Mortality Weekly Report (MMWR) that examined how antibiotic use in hospitals drives resistance and outlined core stewardship principles (CDC MMWR). That report, published in the Morbidity and Mortality Weekly Report, underscored that inpatient facilities could reduce inappropriate prescribing through measures like prospective audit and feedback, formulary restrictions, and clinician education, while still ensuring timely treatment for severe infections. Internationally, the Global Antimicrobial Resistance and Use Surveillance System has begun to harmonize data from dozens of countries, but coverage remains uneven and many low-resource settings still lack basic laboratory capacity.
Evidence continues to show that stewardship programs can reverse some of the damage if they are rigorously implemented. A recent study on hospital-based antibiotic policies, indexed in biomedical literature, found that multifaceted interventions combining guidelines, feedback, and diagnostic support significantly reduced broad-spectrum antibiotic use without increasing mortality. Public health agencies emphasize that stewardship must extend into outpatient clinics, long-term care facilities, and community pharmacies, where large volumes of antibiotics are prescribed for self-limiting viral illnesses. At the same time, public information campaigns can help patients understand why a prescription is not always the safest option, reducing pressure on clinicians to provide antibiotics “just in case.”
National agencies are also working to make technical guidance more accessible to frontline providers and the public. Within the United States, the CDC maintains an extensive online presence explaining resistance mechanisms, prevention strategies, and current data through its main organizational site. Clinicians, researchers, and community members seeking tailored information can contact the agency’s information service, which provides responses to questions on topics ranging from infection control to appropriate prescribing via the CDC-INFO portal. These resources are intended to support local decision-making while reinforcing national priorities such as vaccination, hand hygiene, and environmental cleaning, all of which reduce the need for antibiotics in the first place.
Still, experts caution that surveillance and stewardship alone cannot solve a problem driven by structural inequities and globalized trade. Resistant bacteria and genes move quickly along travel routes, food supply chains, and wastewater streams, undermining efforts that are confined within national borders. That reality has prompted calls for binding international agreements that would set minimum standards for antibiotic use in humans and animals, require investments in water and sanitation infrastructure, and establish predictable financing for research and development. Without such commitments, the world risks a future in which routine surgeries, cancer chemotherapy, and childbirth once again carry unacceptably high risks of untreatable infection.
The trajectory of antimicrobial resistance is not inevitable, but changing it will demand sustained attention across sectors and decades. The science is clear that reducing unnecessary antibiotic exposure, improving infection prevention, and investing in novel therapeutics can slow or even reverse resistance trends. What remains uncertain is whether political leaders, health systems, and industry will align their incentives quickly enough to avert the worst-case scenarios now appearing in long-range forecasts. In the meantime, every prudent prescription, every infection prevented, and every data point reported into national and global surveillance systems represents a small but tangible step away from the edge of a post-antibiotic era.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
